Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target upped by analysts at Wells Fargo & Company from $750.00 to $925.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm currently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s target price points to a potential downside of 0.31% from the stock’s current price.

A number of other research analysts have also recently weighed in on the stock. Citigroup lifted their target price on shares of Regeneron Pharmaceuticals from $740.00 to $825.00 and gave the company a “neutral” rating in a research note on Friday. Guggenheim upped their price objective on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday, September 21st. Bank of America boosted their target price on shares of Regeneron Pharmaceuticals from $908.00 to $1,030.00 and gave the stock a “buy” rating in a report on Monday. Finally, Raymond James Financial raised their target price on shares of Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $878.03.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $927.89 on Monday. The business has a 50-day simple moving average of $793.30 and a two-hundred day simple moving average of $738.05. The stock has a market cap of $95.54 billion, a price-to-earnings ratio of 20.49, a PEG ratio of 1.57 and a beta of 0.10. The company has a quick ratio of 3.66, a current ratio of 4.06 and a debt-to-equity ratio of 0.08. Regeneron Pharmaceuticals has a 52 week low of $591.52 and a 52 week high of $935.35.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $16.51 by $3.56. The company had revenue of $5.12 billion during the quarter, compared to analyst estimates of $4.58 billion. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The firm’s quarterly revenue was up 36.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $11.83 EPS. On average, analysts expect that Regeneron Pharmaceuticals will post 49.10 EPS for the current year.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Huda Zoghbi sold 800 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 31.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the completion of the transaction, the executive vice president directly owned 13,134 shares in the company, valued at $11,163,900. This represents a 8.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 8,093 shares of company stock valued at $6,506,845. Company insiders own 6.97% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of REGN. Orbimed Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the first quarter valued at approximately $11,358,000. BlackRock Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $5,682,636,000. Contravisory Investment Management Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $6,327,000. Oxbow Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $3,342,000. Finally, Deutsche Bank AG purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $323,249,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Strong quarterly results: Regeneron reported $5.12 billion in revenue, up 36% year over year and above the $4.58 billion analyst consensus. Adjusted earnings of $20.07 per share also exceeded expectations of $16.51. Regeneron revenue jumps 36% on a bigger Sanofi profit share
• Positive Sentiment: Dupixent remains the primary growth engine: Global quarterly Dupixent sales rose 35% to approximately $6.5 billion, reinforcing the strength of Regeneron’s collaboration with Sanofi and supporting expectations for continued earnings growth. Regeneron: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Pipeline and commercial catalysts: Investors highlighted encouraging Libtayo data in high-risk skin cancer, an expanded BARDA supply agreement for Ebola treatment, and management’s comments about a deep development pipeline. Ongoing share repurchases may also support per-share results. Regeneron Earnings Call Highlights Explosive Growth, Deep Pipeline
• Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, or $3.76 annualized, payable December 3 to shareholders of record November 20. The approximately 0.4% yield is modest but signals continued shareholder returns.
• Neutral Sentiment: Citigroup has forecast further appreciation, while the stock’s breakout to a two-year and 52-week high reflects strong investor momentum. However, the recent rally raises questions about how much future growth is already reflected in the valuation. Regeneron Bolts Higher on Dupixent Dominance
• Negative Sentiment: At roughly $928 per share, Regeneron has risen substantially and may face profit-taking or valuation pressure if future results do not maintain the current pace of growth. Regeneron Stock Looks At A Discount To Earnings

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.